Ontruzant is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Organon Llc. The primary component is Trastuzumab.
Product ID | 78206-147_ca182adf-2c29-47da-9e4e-e86e4b25cc49 |
NDC | 78206-147 |
Product Type | Human Prescription Drug |
Proprietary Name | Ontruzant |
Generic Name | Trastuzumab |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2021-06-01 |
Marketing Category | BLA / |
Application Number | BLA761100 |
Labeler Name | Organon LLC |
Substance Name | TRASTUZUMAB |
Active Ingredient Strength | 150 mg/1 |
Pharm Classes | HER2/neu Receptor Antagonist [EPC],HER2/Neu/cerbB2 Antagonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-06-01 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
0006-5033 | Ontruzant | trastuzumab |
0006-5034 | Ontruzant | Ontruzant |
50242-132 | Herceptin | Trastuzumab |
50242-134 | Herceptin | Trastuzumab |
50242-333 | Herceptin | Trastuzumab |
63459-303 | HERZUMA | TRASTUZUMAB |
63459-305 | HERZUMA | TRASTUZUMAB |
67457-845 | OGIVRI | trastuzumab |
67457-847 | OGIVRI | trastuzumab |
67457-991 | OGIVRI | trastuzumab |
0069-0305 | Trazimera-qyyp | trastuzumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ONTRUZANT 87405213 not registered Live/Pending |
Merck Sharp & Dohme Corp. 2017-04-10 |
ONTRUZANT 86456110 not registered Dead/Abandoned |
Merck Sharp & Dohme Corp. 2014-11-17 |